Ryvu Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Ryvu Therapeutics stock has a consensus rating of "Buy" and an average price target of zł 33.62. The average 1-year stock price forecast is 118.60% higher than the current stock price, while the lowest is zł 17.00 (+10.53%) and the highest is zł 49.10 (+219.25%).

Price Target: zł 33.62 (+118.60%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	zł 17.00	zł 33.62	zł 29.00	zł 49.10
Change	+10.53%	+118.60%	+88.56%	+219.25%

Analyst Ratings

The average analyst rating for Ryvu Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	3	3	3	3	2
Buy	0	0	0	0	0	0
Hold	1	1	2	2	2	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	5	5	5	5

Financial Forecast

Revenue This Year

121.35M

from 87.70M

38.36%

from 87.70M

Revenue Next Year

82.97M

from 121.35M

-31.63%

from 121.35M

EPS This Year

-2.06

from -4.40

EPS Next Year

-2.25

from -2.06

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	35.41M	68.44M	67.30M	101.96M	87.70M	121.35M
Revenue Growth	-4.16%	93.25%	-1.67%	51.51%	-13.98%	38.36%
Operating Income	-78.89M	-69.49M	-97.38M	-121.97M	-97.21M	-33.33M
Net Income	-79.08M	-83.78M	-92.11M	-111.44M	-101.23M	-31.48M
EPS	-	-	-	-	-4.40	-2.06
Free Cash Flow	-28.13M	-255.29M	196.80M	-59.48M	-82.50M	-42.00M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is PLN.

Revenue Forecast

Revenue	2026	2027	2028
High	225.2M
Avg	121.4M
Low	75.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	156.8%
Avg	38.4%
Low	-13.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.06
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-